已收盤 10-08 16:00:00 美东时间
0.000
0.00%
Mainz Biomed's ColoAlert®, a non-invasive DNA-based colorectal cancer screening test, has been officially registered with the UK's MHRA and authorized for marketing. This milestone, achieved through a partnership with EDX Medical Group, aims to increase accessibility and participation in CRC screening, addressing the UK's fourth most common cancer. ColoAlert detects DNA biomarkers in stool samples, complementing existing screening programs and of...
09-02 12:01
Biomea Fusion announced new data on icovamenib, an oral menin inhibitor, at ADA 2025. Preclinical studies show icovamenib enhances glycemic control and weight loss when combined with low-dose semaglutide, while preserving lean mass. It also rescues human myotube atrophy ex vivo. In the Phase II COVALENT-111 trial, icovamenib achieved a 1.0% placebo-adjusted HbA1c reduction and a 55% increase in C-peptide at Week 26, demonstrating durable effects ...
06-23 11:00